Atopic Dermatitis pathology background / Clinical viewsImavita / Atopic Dermatitis

Atopic Dermatitis or atopic eczema is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Though the condition affects people of all ages, it is primarily common among infants and children. Symptomatic treatment of atopic dermatitis relies primarily on the use of topical formulations (corticosteroids and immunosuppressors). Physicians consider current oral treatments to have limited value in the treatment of atopic dermatitis; antihistamines are the primary class of oral agents used. Due to its chronic and relapsing nature, atopic dermatitis presents a global public health concern, with reported lifetime prevalence ranging between 10%-20% in children and 1%-3% in adults.

That’s the reason why preclinical models of Atopic Dermatitis are needed for testing efficacy prior to clinical testing.
IMAVITA is able now to propose operational efficacy testing service in this pathology.

 

Atopic Dermatitis (AD) preclinical model / Overview

Induced AD in rodents (hapten induced models / IL23-induced / oxazolone or DNCB)

Induced itching in rodents (contact dermatitis itching)

 

Oxazolone-induced AD preclinical model

  • Sensitization and repeated challenge with oxazolone / topically on back and ear
  • Immunocompetent rodent sp.  (Balb/c strain)
  • Clinical endpoints / scoring (equivalent do SCORAD): skin dryness/scaling, skin redness/erythema, skin thickness / edema, excoriations, itching (observed behaviour)
  • Corticoid (betamethasone, clobetasol) or immunosuppressor as positive control
  • Blood samplings for circulating (cytokines)
  • Skin biomarkers analysis
  • Ex vivo imaging (histology HES / IHC / electron microscopy (SEM))
  • Statistical analysis of efficacy data: clinical scoring and histomorphometrics

 

IL23-induced AD preclinical model

  • Repeated intradermal injection of rIL23
  • Immunocompetent rodent sp.  (C57Bl6 strain)
  • Clinical endpoints / scoring (equivalent do SCORAD): skin dryness/scaling, skin redness/erythema, skin thickness / edema, excoriations, itching (observed behaviour)
  • Skin biomarkers analysis
  • Ex vivo imaging (histology HES / IHC / electron microscopy (SEM))
  • Statistical analysis of efficacy data: clinical scoring and histomorphometrics

 

Itching preclinical model

  • Itching alone induction (histamine / SLIGRL peptide)
  • Immunocompetent rodent sp.  (Balb/c & C57Bl6)
  • Evaluation of Animal behaviour observation / Itching scoring / Video recording of behaviour (day light / IR illumination for night recording)

 
For additional informations on preclinical models in the area of atopic dermatitis preclinical models, please inquire
 

On-going R&DR&D Imavita

Development of non invasive imaging evaluation for longitudinal studies (FMT / Fluorescent Tomography & OCT / Optical Coherent Tomograhy)

 

Induction of AD with dust mites extracts

 

Evaluation of microbiota effect on AD pathology development

 

Gravityscan Badge